論文目次 |
目 錄
中文摘要 ............................................................................................................. i
英文摘要 ........................................................................................................... iii
謝誌 .................................................................................................................... v
目錄 ................................................................................................................... vi
圖目錄 ............................................................................................................... xi
縮寫對照表....................................................................................................... xiii
一、 緒 論 ........................................................................................................ 1
二、 結 果 ........................................................................................................ 7
2-1 合成新化合物1-(Hydroxymethyl)-4,5,6,7-tetrabromo-
benzotriazole(18a)與2-(Hydroxymethyl)-4,5,6,7-tetrabromo-
benzotriazole (18b) ......................................................................... 7
2-2 合成新化合物1-(Chloromethyl)-4,5,6,7-tetrabromo-
benzotriazole (19a)與2-(Chloromethyl)-4,5,6,7-tetrabromo-
benzotriazole (19b) ....................................................................... 10
2-3 合成新化合物8-[(4',5',6',7'-Tetrabromobenzotriazol-1'-yl)-
methylthio]adenosine (23) ............................................................. 12
2-4 利用NMR鑑定Adenosine–TBBT conjugate 23之化學位移...... 14
2-5 合成新化合物8-[(4',5',6',7'-Tetrabromobenzotriazol-2'-yl)
methylthio]adenosine (24) ............................................................. 16
2-6 利用NMR鑑定Adenosine–TBBT conjugate 24之化學位移 ..... 18
2-7 合成新化合物8-[(4',5',6',7'-Tetrabromobenzotriazol-1'-yl)
methylthio]adenine (25) ................................................................ 19
2-8 合成新化合物8-[(4',5',6',7'-Tetrabromobenzotriazol-2'-yl)
methylthio]adenine (26) ................................................................ 21
2-9 合成新化合物8-[(4',5',6',7'-Tetrabromobenzotriazol-2'-yl)
methylthio]adenosine (28) …......................................................... 22
三、 討 論 ...................................................................................................... 26
3-1 探討benzotriazole所產生的互變異構 ........................................ 26
3-2 結合核磁共振光譜與分子模擬探討共軛化合物23與28 .......... 28
3-2-1 探討共軛化合物23之S–CH2化學位移 ............................ 28
3-2-2 探討共軛化合物28之醣類一號氫化學位移 .................... 31
3-3 探討親核性取代反應之最佳條件 .............................................. 33
3-3-1 討論pH值對8-Mercaptoadenosine親核性影響 ................ 33
3-3-2 探討8-Mercaptoadenosine中硫原子之親核性質 .............. 34
四、 結 論 ...................................................................................................... 36
五、 實 驗 部 分 .......................................................................................... 38
1-(Hydroxymethyl)-4,5,6,7-tetrabromobenzotriazole (18b) ................... 39
1-(Chloromethyl)-4,5,6,7-tetrabromobenzotriazole (19a) ...................... 39
2-(Chloromethyl)-4,5,6,7-tetrabromobenzotriazole (19b) ...................... 40
8-[(4',5',6',7'-Tetrabromobenzotriazol-1'-yl)methylthio]adenosine (23) . 41
8-[(4',5',6',7'-Tetrabromobenzotriazol-2'-yl)methylthio]adenosine (24) . 41
8-[(Benzimidazol-2'-yl)(phenyl)methylthio]adenosine (28) ................... 42
8-[(4',5',6',7'-Tetrabromobenzotriazol-1'-yl)methylthio]adenine (25) ..... 42
8-[(4',5',6',7'-Tetrabromobenzotriazol-2'-yl)methylthio]adenine (26) ..... 43
六、 參 考 文 獻 .......................................................................................... 44
七、 光 譜 ...................................................................................................... 52
2-(Hydroxymethyl)-4,5,6,7-tetrabromobenzotriazole (18b)
1H核磁共振光譜圖 ............................................................................... 53
2-(Hydroxymethyl)-4,5,6,7-tetrabromobenzotriazole (18b)
13C核磁共振光譜圖 .............................................................................. 53
2-(Hydroxymethyl)-4,5,6,7-tetrabromobenzotriazole (18b)
紅外分光光譜圖 .................................................................................... 54
1-(Chloromethyl)-4,5,6,7-tetrabromobenzotriazole (19a)
1H核磁共振光譜圖 ............................................................................... 54
1-(Chloromethyl)-4,5,6,7-tetrabromobenzotriazole (19a)
13C核磁共振光譜圖 .............................................................................. 55
1-(Chloromethyl)-4,5,6,7-tetrabromobenzotriazole (19a)
紅外分光光譜圖 .................................................................................... 55
2-(Chloromethyl)-4,5,6,7-tetrabromobenzotriazole (19b)
1H核磁共振光譜圖 ............................................................................... 56
2-(Chloromethyl)-4,5,6,7-tetrabromobenzotriazole (19b)
13C核磁共振光譜圖 .............................................................................. 56
2-(Chloromethyl)-4,5,6,7-tetrabromobenzotriazole (19b)
紅外分光光譜圖 .................................................................................... 57
8-[(4',5',6',7'-Tetrabromobenzotriazol-1'-yl)methylthio]adenosine (23)
1H核磁共振光譜圖 ............................................................................... 57
8-[(4',5',6',7'-Tetrabromobenzotriazol-1'-yl)methylthio]adenosine (23)
13C 核磁共振光譜圖 ............................................................................. 58
8-[(4',5',6',7'-Tetrabromobenzotriazol-1'-yl)methylthio]adenosine (23)
紅外分光光譜 ........................................................................................ 58
8-[(4',5',6',7'-Tetrabromobenzotriazol-2'-yl)methylthio]adenosine (24)
1H核磁共振光譜圖 ............................................................................... 59
8-[(4',5',6',7'-Tetrabromobenzotriazol-2'-yl)methylthio]adenosine (24)
13C核磁共振光譜圖 .............................................................................. 59
8-[(4',5',6',7'-Tetrabromobenzotriazol-2'-yl)methylthio]adenosine (24)
紅外分光光譜 ........................................................................................ 60
8-[(benzimidazol-2-yl)(phenyl)methylthio]adenosine (28)
1H核磁共振光譜圖 ............................................................................... 60
8-[(benzimidazol-2-yl)(phenyl)methylthio]adenosine (28)
紅外分光光譜 ........................................................................................ 61
8-[(4',5',6',7'-Tetrabromobenzotriazol-1'-yl)methylthio]adenine (25)
1H核磁共振光譜圖 ............................................................................... 61
8-[(4',5',6',7'-Tetrabromobenzotriazol-1'-yl)methylthio]adenine (25)
紅外分光光譜 ........................................................................................ 62
8-[(4',5',6',7'-Tetrabromobenzotriazol-2'-yl)methylthio]adenine (26)
1H核磁共振光譜圖 ............................................................................... 62
8-[(4',5',6',7'-Tetrabromobenzotriazol-2'-yl)methylthio]adenine (26)
紅外分光光譜 ........................................................................................ 63
|
參考文獻 |
六、參 考 文 獻 (References)
1. Neyts, J.; Leyssen, P.; De Clercq, E. Antiviral drugs in current clinical use. Antiviral Res. 2008, 78, 9–25.
2. Seventh Framework Programme home page. http://cordis.europa.eu/fp7/home_en.html
3. Maryanoff, B. E. Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G. J. Med. Chem. 2004, 47, 669–787.
4. Mileni, M.; Garfunkle, J.; Ezzili, C.; Scott Kimball, F.; Cravatt, B. F.; Stevens, R. C.; Boger, D. L. X-ray crystallographic analysis of ?-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. J. Med. Chem. 2010, 53, 230–240.
5. Jonathan Fray, M.; Bull, D. J.; Carr, C. L.; Gautier, E. C. L.; Mowbray, C. E.; Stobie, A. Structure–activity relationships of 1,4-dihydro-(1H,4H)-quinoxaline-2,3-diones as N-methyl-D-aspartate (glycine site) receptor antagonists. 1. heterocyclic substituted 5-alkyl derivatives. J. Med. Chem. 2001, 44, 1951–1962.
6. Graneto, M. J.; Kurumbail, R. G.; Vazquez, M. L.; Shieh, H. -S.; Pawlitz, J. L.; Williams, J. M.; Stallings, W. C.; Geng, L.; Naraian, A. S.; Koszyk, F. J.; Stealey, M. A.; Xu, X. D.; Weier, R. M.; Hanson, G. J.; Mourey, R. J.; Compton, R. P.; Mnich, S. J.; Anderson, G. D.; Monahan, J. B.; Devraj, R. Synthesis, crystal structure, and activity of pyrazole–based inhibitors of p38 kinase. J. Med. Chem. 2007, 50, 5712–5719.
7. Kim, Y. S. and Milner, J. A. Targets for indole-3-carbinol in cancer prevention. J. Nutr. Biochem. 2005, 16, 65–73.
8. Takeuchi, T.; Oishi, S.; Watanabe, T.; Ohno, H.; Sawada, J.; Matsuno, K.; Asai, A.; Asada, N.; Kitaura, K.; Fujii, N. Structure–activity relationships of carboline and carbazole derivatives as a novel class of ATP–competitive kinesin spindle protein inhibitors. J. Med. Chem. 2011, 54, 4839–4846.
9. Beghyn, T. B.; Charton, J.; Leroux, F.; Laconde, G.; Bourin, A.; Cos, P.; Maes, L.; Deprez, B. Drug to genome to drug: discovery of new antiplasmodial compounds. J. Med. Chem. 2011, 54, 3222–3240.
10. Li, Y.-F.; Wang, G.-F.; He, P,-L.; Huang, W.-G.; Zhu, F.-H.; Gao, H.-Y.; Tang, W.; Luo, Y.; Feng, C.-L.; Shi, L.-P.; Ren, Y.-D.; Lu, W.; Zuo, J.-P. Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives. J. Med. Chem. 2006, 49, 4790–4794.
11. Ndakala, A. J.; Gessner, R. K.; Gitari, P. W.; October, N.; White, K. L.; Hudson, A.; Fakorede, F.; Shackleford, D. M.; Kaiser, M.; Yeates, C.; Charman, S. A.; Chibale, K. Antimalarial pyrido[1,2-а]benzimidazoles. J. Med. Chem. 2011, 54, 4581–4589.
12. Kazmierski, W. M.; Anderson, D. L.; Aquino, C.; Chauder, B. A.; Duan, M.; Ferris, R.; Kenakin, T.; Koble, C. S.; Lang, D. G.; Mcintyre, M. S.; Peckham, J.; Watson, C.; Wheelan, P.; Spaltenstein, A.; Wire, M. B.; Svolto, A.; Youngman, M. Novel 4,4-disubstituted piperidine–based C–C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile. J. Med. Chem. 2011, 54, 3756–3767.
13. Wu, C.-Y.; King, K.-Y.; Kuo, C.-J.; Fang, J.-M.; Wu, Y.-T.; Ho, M.-Y; Liao, C.-L, Shie, J.-J.; Liang, P.-H.; Wong, C.-H. Stable benzotriazole esters as mechanism–based inactivators of the severe acute respiratory syndrome 3CL protease. Chem. Biol. 2006, 13, 261–268.
14. Lilienkampf, A.; Mao, J.; Wan, B.; Wang, Y.; Franzblau, S. G.; Kozikowski, A. P. Structure–activity relationships for a series of quinoline–based compounds active against replicating and nonreplicating mycobacterium tuberculosis J. Med. Chem. 2009, 52, 2109–2118.
15. Tseng, C.-H.; Lin, R.-W.; Chen, Y.-L.; Wang, G.-J.; Ho, M.-L.; Tzeng, C.-C. Discovery of indeno[1,2-c]quinoline derivatives as inhibitors of osteoclastogenesis induced by receptor activator of NF-?B ligand (RANKL). J. Med. Chem. 2011, 54, 3103–3107.
16. Chen, Y.-W.; Chen, Y.-L.; Tseng, C-H.; Liang, C.-C.; Yang, C.-N.; Yao, Y.-C.; Lu, P.-J.; Tzeng, C.-C. Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non–small–cell lung cancers. J. Med. Chem. 2011, 54, 4446–4461.
17. Singh, P.; Kaur, J.; Kaur, P.; Kaur, S. Search for MDR modulators: design, syntheses and evaluations of N-substituted acridones for interactions with p-glycoprotein and Mg2+. Bioorg. Med. Chem. 2009, 17, 2423–2427.
18. Manfroni, G.; Paeshuyse, J.; Massari, S.; Zanoli, S.; Gatto, B.; Maga, G.; Tabarrini, O.; Cecchetti, V.; Fravolini, A.; Neyts, J. Inhibition of subgenomic hepatitis C virus RNA replication by acridone derivatives: identification of an NS3 helicase inhibitor. J. Med. Chem. 2009, 52, 3354–3365.
19. Tabarrini, O.; Manfroni, G.; Fravolini, A.; Cecchetti, V.; Sabatini, S.; De Clercq, E.; Rozenski, J.; Canard, B.; Dutartre, H.; Paeshuyse, J.; Neyts, J. Synthesis and anti-BVDV activity of acridones as new potential antiviral agents. J. Med. Chem. 2006, 49, 2621–2627.
20. Chen, J. J.; Wei, Y.; Drach, J. C.; Townsend, L. B. Synthesis and antiviral evaluation of trisubstituted indole N-nucleosides as analogues of 2,5,6-trichloro-1-(?-D-ribofuranosyl) benzimidazole (TCRB). J. Med. Chem. 2000, 43, 2449–2456.
21. Harper, S.; Avolio, S.; Pacini, B.; Filippo, M. D.; Altamura, S.; Tomei, L.; Paonessa, G.; Marco, S. D; Carfi, A.; Giuliano, C.; Padron, J.; Bonelli, F.; Migliaccio, G.; Francesco, R. L.; Rowley, M.; Narjes, F. Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. J. Med. Chem. 2005, 48, 4547–4557.
22. Porcari, A. R.; Devivar, R. V.; Kucera, L. S.; Drach, J. C.; Townsend, L. B. Design, synthesis, and antiviral evaluations of 1-(substituted benzyl)-2-substituted-5,6- dichlorobenzimidazoles as nonnucleoside analogues of 2,5,6-trichloro-1-(?-D- ribofuranosyl)benzimidazole. J. Med. Chem. 1998, 41, 1252–1262.
23. Keller, L.; Beaumont, S.; Liu, J. -M.; Thoret, S.; Bignon, J. S.; Wdzieczak–Bakala, J.; Dauban, P.; Dodd, R. H. New C5–alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities. J. Med. Chem. 2008, 51, 3414–3421.
24. Nien, C.-Y.; Chen, Y.-C.; Kuo, C.-C.; Hsieh, H.-P.; Chang, C.-Y.; Wu, J.-S.; Wu, S.-Y.; Liou, J.-P.; Chang, J.-Y. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J. Med. Chem. 2010, 53, 2309–2313.
25. Manohar, S.; Khan, S. I.; Rawat, D. S. Synthesis, antimalarial activity and cytotoxicity of 4-aminoquinoline-triazine conjugates. Bioorg. Med. Chem. Lett. 2010, 20, 322–325.
26. Delmas, F.; Avellaneda, A.; Di Giorgio, C.; Robin, M.; De Clercq, E.; Timon–David, P.; Galy, J.-P. Synthesis and antileishmanial activity of (1,3-benzothiazol-2-yl)- amino-9-(10H)-acridinone derivatives. Eur. J. Med. Chem. 2004, 39, 685–690.
27. Ghosh, B.; Antonio, T.; Zhen, J.; Kharkar, P.; Reith, Maarten E. A.; Dutta, A. K. Development of (S)-N6-(2-(4-(Isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7- tetrahydrobenzo[d]-thiazole-2,6-diamine and Its analogue as a D3 receptor preferring agonist: potent in vivo activity in parkinson’s disease animal models. J. Med. Chem. 2010, 53, 1023–1037.
28. Wikel, J. H.; Paget, C. J.; Delong, D. C.; Nelson, J. D.; Wu, C. Y. E.; Paschal, J. W.; Dinner, A.; Templeton. R. J.; Chaney, M. O.; Jones, N. D.; Chamberlin J. W. Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]- 1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication J. Med. Chem. 1980, 23, 368–372.
29. Langford, M. P.; Ball, W. A.; Ganley. J. P. Inhibition of the enteroviruses that cause acute hemorrhagic conjunctivitis (AHC) by benzimidazoles; Enviroxime (LY 122772) and Enviradone (LY 127123). Antiviral Res. 1995, 27, 355–365.
30. De Palma, A. M.; Heggermont, W.; Leyssen, P.; Pürstinger, G.; Wimmer, E.; De Clercq, E.; Rao, A.; Monforte, A.-M.; Chimirri, A.; Neyts, J. Anti–enterovirus activity and structure–activity relationship of a series of 2,6-dihalophenyl-substituted- 1H,3H-thiazolo[3,4-a]benzimidazoles. Biochem. Biophys. Res. Commun. 2007, 353, 628–632.
31. Tamm, I.; Bablanian, R.; Nemes, M. M.; Shunk, C. H.; Robinson, F. M.; Folkers, K. Relationship between structure of benzimidazole derivatives and selective virus inhibitory activity. J. Exp. Med. 1961, 113, 625–656.
32. Borowski, P.; Deinert, J.; Schalinski, S.; Bretner, M.; Ginalski, K.; Kulikowski, T.; Shugar, D. Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. Eur. J. Biochem. 2003, 270, 1645–1653.
33. Neyts, J.; De Clercq, E.; Singha, R.; Chang, Y. H.; Das, A. R.; Chakraborty, S. K.; Hong, S. C.; Tsay, S.-C.; Hsu, M.-H.; Hwu, J. R. Structure–activity relationship of new anti-hepatitis C virus agents: heterobicycle coumarin conjugates. J. Med. Chem. 2009, 52, 1486–1490.
34. De Clercq, E. The design of drugs for HIV and HCV. Nature 2007, 6, 1001–1018.
35. Shugar, D.; Zien, P.; Bretner, M.; Zastazpiło, K.; Szyszka, R. Selectivity of 4,5,6,7-tetrabromobenzimidazole as an ATP–competitive potent inhibitor of protein kinase CK2 from various sources. Biochem. Biophys. Res. Commun. 2003, 306, 129–133.
36. Schnopp, M. and Haberhauer, G. Highly selective recognition of ?-chiral primary organoammonium ions by C3–symmetric peptide receptors. Eur. J. Org. Chem. 2009, 26, 4458–4467.
37. Katritzky, A. R.; Oniciu, D. C.; Serdyuk, L.; Ghiviriga, I. Study of the orientation of lithiation of 1- and 2-alkylbenzotriazoles. J. Org. Chem. 1995, 60, 1244–1249.
38. Holmes, R. E. and Robins, R. K. Purine nucleosides. VII. Direct bromination of adenosine, deoxyadenosine, guanosine, and related purine nucleosides. J. Am. Chem. Soc. 1964, 86, 1242–1245.
39. Hwu, J. R.; Lin, S.-Y.; Tsay, S.-C.; De Clercq, E.; Leyssen, P.; Neyts, J. Coumarin–purine ribofuranoside conjugates as new agents against hepatitis C virus. J. Med. Chem. 2011, 54, 2114–2126.
40. Gualtieri, F.; Brody, G.; Fieldsteel, A. H.; Skinner, W. A. Antiviral agents. 2. Analogs of 2-(?-hydroxybenzyl)benzimidazole. J. Med. Chem. 1972, 15, 420–422.
41. Katritzky, A. R.; Rachwal, S.; Rachwal, B. The chemistry of N–substituted benzotriazoles. Part 2. Reactions of benzotriazole with aldehydes and aldehyde derivatives. 1-(?-hydroxyalkyl)-, 1-(?-alkoxyaIkyl)-, and 1-(?-acyloxyalkyl)- benzotriazoles. J. Chem. Soc. Perkin Trans. 1 1987, 791–797.
42. Katritzky, A. R.; Perumal, S.; Savage, P. An NMR study of the equilibria involved with benzotriazole, carbonyl compounds, and their adducts. J. Chem. Soc. Perkin Trans. 2 1990, 921–924.
43. Attardo, G. and Tripathy, S. Eur. Patent WO 2010132999, 2010.
44. Giessner–Prettre, C. and Pullman, B. Ring–current effects in the nmr of nucleic acids: a graphical approach. Biopolymers 1976, 15, 2277–2286.
45. Brooks, B. R.; Brooks, C. L.; Mackerell, A. D.; Nillson, L.; Petrelia, R. J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; Cui, Q.; Dinner, A. R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R. W.; Post, C. B.; Pu, J. Z.; Schaefer, M.; Tidor, B.; Venable, R. M.; Woodcock, H. L.; Wu, X.; Yang, W.; York, D. M.; Karplus, M. CHARMM: the biomolecular simulation program. J. Comput. Chem. 2009, 30, 1545–1614.
46. Janiak, C. Dalton Trans. 2000, 3885–3896.
47. Åström, H.; Limén, E.; Strömberg, R. Acidity of secondary hydroxyls in ATP and adenosine analogues and the question of a 2',3'-hydrogen bond in ribonucleosides. J. Am. Chem. Soc. 2004, 126, 14710–14711.
48. Refaey, S. A. M.; Taha, F.; Abd El–Malak A. M. Corrosion and inhibition of 316L stainless steel in neutral medium by 2-mercaptobenzimidazole. Int. J. Electrochem. Sci. 2006, 80–91.
49. Šponer, J. E.; Leszczynski, J.; Glahé, F.; Lippert, B.; Šponer, J. Protonation of platinated adenine nucleobases. Gas phase vs condensed phase picture. Inorg. Chem. 2001, 40, 3269–3278.
50. Sanina, N.; Roudneva, T.; Shilov, G.; Morgunov, R.; Ovanesyan, N.; Aldoshin, S. Structure and properties of binuclear nitrosyl iron complex with benzimidazole-2-thiolyl. Dalton Trans. 2009, 1703–1706.
51. Folchetti, N; Challice, J.; Mullaney, R. Organic Chemistry, 6th ed.; Pearson Prentice Hall, London, 2006; pp 451–452.
52. Kaiya, T; Tanaka, H.; Kohda, K. Formation of 2'-deoxy-2-nitroadenosines by reaction of 2'-deoxyadenosines with copper(II) nitrate/acetic anhydride. Nucleosides, Nucleotides & Nucleic Acids 2002, 21, 427–433.
53. Pinna, L. A.; Pagano, M. A.; Andrzejewska, M. A.; Ruzzene, M.; Sarno, S.; Cesaro, L.; Bain, J.; Elliott, M.; Meggio, F.; Kazimierczuk, Z. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J. Med. Chem. 2004, 47, 6239–6247.
54. Katritzky, A. R.; Lan, X.; Yang, L. Z.; Denisko, O. V. Properties and synthetic utility of N-substituted benzotriazoles. Chem. Rev. 1998, 98, 409−548.
55. Meyer, R. B. and Skibo, B. O. Inhibition of inosinic acid dehydrogenase by 8-substituted purine nucleotides. J. Med. Chem. 1981, 24, 1155–1161.
56. Markland, W.; McQuaid, T. J.; Jain, J.; Kwong, A. D. AAC, Antimicrob Agents 2000, 44, 859–866.
|